Crescent Biopharma (CBIO) Net Cash Flow (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Net Cash Flow of -$17.6 million for Q2 2026, down 113.48% year-over-year from $130.3 million in Q2 2025, and up 26.88% quarter-over-quarter from -$24.0 million in Q1 2026.
Crescent Biopharma (CBIO) Net Cash Flow (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Net Cash Flow for 14 consecutive years, with -$17.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Cash Flow fell 113.48% year-over-year to -$17.6 million; the TTM figure through Jun 2026 stood at $18.9 million (down 87.59% YoY), while the FY2025 annual figure was $178.5 million, up 674.53% from the prior year.
- Net Cash Flow rose to -$17.6 million in Q2 2026 per CBIO's latest filing, from -$24.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $130.3 million in Q2 2025 and bottomed at -$24.0 million in Q1 2026.
- Historically, Net Cash Flow has averaged $5.9 million across 5 years, with a median of -$8.6 million in 2023.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 201.0% — and 2025, when it soared 1565.05%.
- Crescent Biopharma's Net Cash Flow stood at -$7.9 million in 2022, then increased by 3.75% to -$7.6 million in 2023, then soared by 556.56% to $34.8 million in 2024, then soared by 129.92% to $79.9 million in 2025, then tumbled by 121.98% to -$17.6 million in 2026.
- Business Quant data shows CBIO's Net Cash Flow at -$17.6 million in Q2 2026, -$24.0 million in Q1 2026, and $79.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | -17.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.57 Mn |
| Jun 30, 2026 | -17.57 Mn |
| Mar 31, 2026 | -23.99 Mn |
| Mar 31, 2026 | -23.99 Mn |
| Dec 31, 2025 | 79.94 Mn |
| Dec 31, 2025 | 79.94 Mn |
| Sep 30, 2025 | -19.34 Mn |
| Sep 30, 2025 | -19.34 Mn |
| Jun 30, 2025 | 130.28 Mn |
| Jun 30, 2025 | 130.28 Mn |
| Mar 31, 2025 | -12.34 Mn |
| Mar 31, 2025 | -12.34 Mn |
| Dec 31, 2024 | 34.77 Mn |
| Dec 31, 2024 | 34.77 Mn |
| Jun 30, 2024 | -8.89 Mn |
| Jun 30, 2024 | -8.89 Mn |
| Mar 31, 2024 | -10.51 Mn |
| Mar 31, 2024 | -10.51 Mn |
| Dec 31, 2023 | -7.61 Mn |
| Dec 31, 2023 | -7.61 Mn |